Peddock Capital Advisors LLC Sells 151 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Peddock Capital Advisors LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,683 shares of the medical research company’s stock after selling 151 shares during the period. Thermo Fisher Scientific comprises 1.0% of Peddock Capital Advisors LLC’s portfolio, making the stock its 22nd largest holding. Peddock Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,997,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Courier Capital LLC grew its holdings in Thermo Fisher Scientific by 148.8% during the 4th quarter. Courier Capital LLC now owns 20,914 shares of the medical research company’s stock valued at $10,880,000 after buying an additional 12,509 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in Thermo Fisher Scientific by 2.0% in the 4th quarter. Pallas Capital Advisors LLC now owns 11,985 shares of the medical research company’s stock worth $6,235,000 after purchasing an additional 233 shares in the last quarter. Marshall & Sullivan Inc. WA grew its position in shares of Thermo Fisher Scientific by 0.4% during the fourth quarter. Marshall & Sullivan Inc. WA now owns 8,784 shares of the medical research company’s stock valued at $4,570,000 after purchasing an additional 38 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 11.7% during the fourth quarter. Sivia Capital Partners LLC now owns 733 shares of the medical research company’s stock valued at $381,000 after buying an additional 77 shares during the last quarter. Finally, Talbot Financial LLC increased its position in Thermo Fisher Scientific by 6.4% in the fourth quarter. Talbot Financial LLC now owns 17,582 shares of the medical research company’s stock worth $9,147,000 after purchasing an additional 1,062 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TMO shares. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. TD Cowen raised their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Barclays reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Stock Performance

TMO traded up $13.60 during trading on Monday, reaching $555.91. 2,251,816 shares of the company’s stock were exchanged, compared to its average volume of 2,022,951. The stock has a market capitalization of $212.64 billion, a P/E ratio of 34.85, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76. The company’s fifty day simple moving average is $529.91 and its 200-day simple moving average is $568.06. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.69 earnings per share. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock valued at $25,954,465 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.